Table 1.
Clinical and biochemical data of all patients and per group
| All, n = 17 | Group 1, n = 11 Additional information |
Group 2, n = 6 Radiological diagnosis |
|
|---|---|---|---|
| Sex (female) | 13 (76.5%) | 7 (63.6%) | 6 (100%) |
| Age (years)a | 37 (24–59) | 38 (30–59) | 36 (24–49) |
| Duration of disease (years)a | 6 (1–13) | 7 (3–13) | 5.5 (1–12) |
| Prolactin at diagnosis (xULN) | 7.2 (3.3-794.9) | 8.3 (4.1-794.9) | 4.3 (3.3–15.0) |
| MRI at diagnosis | |||
| No adenoma | 3 (17.6%) | 2 (18.2%) | 1 (16.7%) |
| Microadenoma | 8 (47.1%) | 6 (54.5%) | 2 (33.3%) |
| Macroadenoma | 6 (35.3%) | 3 (27.3%) | 3 (50.0%) |
| Giant adenoma | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Cavernous sinus invasion | |||
| Certain | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Possible | 2 (11.8%) | 2 (18.2%) | 0 (0.0%) |
| Unknown | 2 (11.8%) | 0 (0.0%) | 2 (33.3%) |
| Prior treatment | |||
| Surgery | 9 (52.9%) | 6 (54.5%) | 3 (50.0%) |
| Medication (DA) | 17 (100.0%) | 11 (100.0%) | 6 (100.0%) |
| Duration of medical treatment b | |||
| < 6 months | 3 (17.6%) | 2 (18.2%) | 1 (16.7%) |
| 6 months – 1 year | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| > 1 year | 11 (64.7%) | 6 (54.5%) | 5 (83.3%) |
| Hormone levels at time of [ 18 F]FET-PET/MRI CR | |||
| Prolactin at [18F]FET-PET/MRICR (xULN)c | 3.6 (1.0-20.3) | 3.4 (1.0-20.3) | 5.5 (2.1–10.8) |
| MRI before [ 18 F]FET-PET/MRI CR | |||
| Macroadenoma remnant | 1 (5.9%) | 1 (9.1%) | 0 (0.0%) |
| Microadenoma remnant | 2 (11.8%) | 2 (18.2%) | 0 (0.0%) |
| No remnant | 6 (35.3%) | 0 (0.0%) | 6 (100.0%) |
| Possible adenoma remnant | 4 (23.5%) | 4 (36.4%) | 0 (0.0%) |
| Possible multifocal remnant | 4 (23.5%) | 4 (36.4%) | 0 (0.0%) |
| [ 18 F] FET-PET/MRI CR | |||
| One active lesion concordant with MRId | 9 (52.3%) | 9 (81.8%) | 0 (0.0%) |
| One active lesion not identified with MRI | 4 (23.5%) | 0 (0.0%) | 4 (66.7%) |
| No active lesion | 3 (17.6%) | 1 (9.1%)e | 2 (33.3%) |
| Multifocal active lesion | 1 (5.9%) | 1 (9.1%) | 0 (0.0%) |
| Treatment advice based on [ 18 F]FET-PET/MRI CR | |||
| Surgery offered | 11 (64.7%) | 8 (72.7%) | 3 (50.0%) |
| No surgery | 6 (35.3%) | 3 (27.3%) | 3 (50.0%) |
Values are presented as median (range), or number (percentage)
DA dopamine agonist, xULN times upper limit of normal
a At time of [18F]FET-PET/MRICR
b Missing data, n = 3
c Dopamine agonists were discontinued > 4 weeks before [18F]FET-PET/MRICR in all patients
d The lesion on [18F]FET-PET/MRICR corresponded with one out of two possible lesions in the patients with suspicion of a multifocal lesion on conventional MRI (n = 2)
e Inconclusive result due to diffuse tracer uptake in the sellar region